Hengrui’s Docetaxel Use Ruled Not Infringing On Sanofi-Aventis’ Patent
This article was originally published in PharmAsia News
Executive Summary
Hengrui China's Patent Re-examination Board of the State Intellectual Property Office (SIPO) has ruled that the patent right of Aventis Pharma S.A. and Sanofi-Aventis for Docetaxel is invalid. If dissatisfied with the verdict, the plaintiffs can appeal to the Beijing Number One Intermediate People's Court within three months. Last September, Aventis Pharma and Sanofi-Aventis sued Jiangsu Hengrui in Beijing Municipal Higher People's Court for Docetaxel patent infringement, asking for patent fees of 45 million yuan ($6.4 million), financial loss compensation of 55 million yuan ($7.87 million), miscellaneous expenses of 200,000 yuan ($28,000) and full cost of the litigation. (Click here for more - Chinese language)